



Seeding Success

The below start-ups based on promising OHSU technologies have benefited from philanthropic contributions at critical points in their development:

Start-up: Gamma Therapeutics

Innovation: Test for measuring risk of cardiovascular disease

David Farrell, Ph.D., a professor of pathology at OHSU School of Medicine, founded Gamma Therapeutics (GT) to commercialize better tests for predicting heart disease. After GT received funds from the Innovation & Seed Fund to incorporate in 2009, it qualified for nearly \$2 million in grant funding to launch the company. GT is developing a range of products that will help people with heart disease, and is expanding into new technologies for incision closure, wound closure and fast-clotting bandages for soldiers wounded in combat.

Start-up: Yecuris Corporation

Innovation: Technology for growing "humanized" liver cells

Based on scientific advances related to pediatric liver disease made by Markus Grompe, M.D., and colleagues at the OHSU Papé Pediatric Research Institute, this Portland start-up has been operating since 2007. An Innovation & Seed Fund award allowed Yecuris to show broader uses for their technologies, including treating chronic and acute liver disease, testing for drug toxicity, and growing healthy human cells that could one day be transferred to a patient.

For information on making a gift to the OHSU Innovation & Seed Fund, call Chris Tye at 503 494-0104.

BY THE NUMBERS

OHSU Technology Transfer

Since 2002:

45

Number of spin-off companies

143

Approximate number of people employed by spin-off companies

FY11 Research Strengths

\$358 million

Contributed to regional economy from OHSU research

1,131

Number of OHSU principal investigators

4,500

Number of ongoing research projects

118

Number of industry-sponsored research agreements

